March 2, 2025 - 21:02

A U.S. federal judge has turned down a proposed $27.5 million class-action settlement in a lawsuit against Align Technology, the company known for its dental products, including clear aligners. The lawsuit alleges that Align engaged in anti-competitive practices that harmed both consumers and competitors in the orthodontic market.
The judge expressed concerns regarding the adequacy of the settlement, questioning whether it sufficiently addressed the claims made by the plaintiffs. This ruling comes as a significant development in a case that has drawn attention to the competitive dynamics within the dental industry.
The plaintiffs had argued that Align's actions stifled competition and led to higher prices for consumers seeking orthodontic treatment. The rejection of the settlement means that the case will continue, potentially leading to a trial where further evidence and arguments will be presented.
This decision highlights the ongoing scrutiny of corporate practices in the healthcare sector and the legal system's role in ensuring fair competition.
September 30, 2026 - 21:59
Micron Technology Tops Lofty Fiscal Q4 Goals, Guides Above ViewsMicron Technology exceeded analyst expectations for its fiscal fourth quarter, delivering results that outperformed even the most optimistic projections on Wall Street. The memory chip maker...
September 30, 2026 - 01:50
Space Force Turns to Laser Systems to Shield Launch Sites from Drone ThreatsThe U.S. Space Force is moving forward with plans to deploy laser technology as part of a broader effort to defend its launch facilities from unauthorized drones. The initiative focuses on...
September 29, 2026 - 04:58
DIU Seeks Investors in Counter-Unmanned Systems TechnologyThe Defense Innovation Unit is looking for private investors to back companies working on counter unmanned systems technology. The effort targets firms building tools to detect, track, and disable...
September 28, 2026 - 02:02
Novo Nordisk (CPSE:NOVO B) Secures Long-Acting Injectable Technology In €1.165 Billion Nanexa Licensing AgreementNovo Nordisk has entered a global licensing agreement with Swedish drug delivery company Nanexa, valued at up to 1.165 billion euros. The deal centers on Nanexa`s PharmaShell technology, a platform...